Swiss National Bank grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 5.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 75,900 shares of the company’s stock after acquiring an additional 3,700 shares during the period. Swiss National Bank owned about 0.18% of Omnicell worth $6,530,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new position in Omnicell in the fourth quarter worth approximately $12,125,000. Parallel Advisors LLC bought a new position in Omnicell in the first quarter worth approximately $28,000. Bessemer Group Inc. raised its position in Omnicell by 2,209.1% in the second quarter. Bessemer Group Inc. now owns 25,400 shares of the company’s stock worth $2,185,000 after acquiring an additional 24,300 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Omnicell by 1.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 12,200 shares of the company’s stock worth $1,050,000 after acquiring an additional 210 shares during the period. Finally, South Dakota Investment Council raised its position in Omnicell by 12.2% in the first quarter. South Dakota Investment Council now owns 5,500 shares of the company’s stock worth $445,000 after acquiring an additional 600 shares during the period. Institutional investors own 95.22% of the company’s stock.
In other Omnicell news, Chairman Randall A. Lipps sold 5,000 shares of Omnicell stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $70.30, for a total value of $351,500.00. Following the completion of the transaction, the chairman now directly owns 140,506 shares of the company’s stock, valued at approximately $9,877,571.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dan S. Johnston sold 9,929 shares of Omnicell stock in a transaction on Friday, June 28th. The stock was sold at an average price of $85.47, for a total transaction of $848,631.63. Following the completion of the transaction, the executive vice president now directly owns 31,505 shares of the company’s stock, valued at $2,692,732.35. The disclosure for this sale can be found here. Insiders sold a total of 28,077 shares of company stock valued at $2,287,265 over the last three months. Corporate insiders own 2.77% of the company’s stock.
OMCL opened at $70.39 on Wednesday. The stock has a market capitalization of $2.96 billion, a price-to-earnings ratio of 46.01, a PEG ratio of 2.31 and a beta of 1.11. The company has a fifty day moving average of $71.86 and a 200 day moving average of $79.43. Omnicell, Inc. has a fifty-two week low of $56.96 and a fifty-two week high of $92.59. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.54 and a current ratio of 2.03.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 25th. The company reported $0.51 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.04. The company had revenue of $217.40 million during the quarter, compared to analysts’ expectations of $214.13 million. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. Omnicell’s quarterly revenue was up 15.2% on a year-over-year basis. During the same period last year, the company posted $0.46 earnings per share. On average, equities research analysts forecast that Omnicell, Inc. will post 2.04 earnings per share for the current year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Recommended Story: Trading Strategy Examples and Plans
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.